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Objective Biomarkers that are associated with future progression to rheumatoid arthritis (RA) and joint destruction have been
discovered previously in patients with arthralgia. The present study examined these RA biomarkers in inflammatory bowel disease
(IBD) patients with arthropathies.
Patients and methods Sera from 155 IBD patients with and 99 IBD patients without arthropathies were analyzed for
immunoglobulin (Ig) M rheumatoid factor (RF), IgA-RF, anti-cyclic citrullinated peptide 2, anti-cyclic citrullinated peptide 3.1, and
anti-carbamylated protein antibody positivity using enzyme-linked immunosorbent assays. The prevalence of the autoantibodies
in the IBD patients was compared with the prevalence in RA patients.
Results No differences were found in biomarker positivity between IBD patients with and without arthropathies. Significantly
more biomarker positivity (P<0.001) was observed in RA patients compared with IBD patients with arthropathies. Also, smoking
turned out to be significantly associated with positivity for IgM-RF or IgA-RF.
Conclusion Our findings suggest that there is no apparent clinical value in the detection of RA biomarkers in serum of IBD
patients to help identify arthropathies. Eur J Gastroenterol Hepatol 29:345–348
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
Introduction
Rheumatoid arthritis (RA) is a chronic systemic auto-
immune disease characterized by destructive polyarthritis,
which leads to disability and increased mortality [1]. Early
diagnosis and initiation of treatment is important in RA as
a considerable number of patients develop irreversible
joint damage shortly after disease onset [2,3].
Serological biomarkers, including rheumatoid factor
(RF), anti-citrullinated protein antibodies (ACPA), and
anti-carbamylated protein antibodies (anti-CarP), have
previously been reported to be important diagnostic mar-
kers and predictive factors for the development of RA in
an early stage [4–10]. RF is an autoantibody directed
against the Fc region of immunoglobulin (Ig) G and
commonly detected in RA, but can also be positive in
patients with other autoimmune and nonautoimmune
diseases as well as in healthy individuals [4]. ACPA are
often detected using assays based on cyclic citrullinated
peptides (CCP), such as the CCP2 and CCP3 assays.
Citrullination is the conversion of the amino acid arginine
into citrulline, mediated by peptidylarginine deiminase [5,6].
Anti-CCP antibodies are highly specific (up to 99%) for
RA, but less sensitive compared with RF. Testing for RF
and ACPA simultaneously has been suggested to improve
sensitivity. Recently, an anti-CCP3.1 assay was developed
that detects both IgG and IgA anti-CCP antibodies to
improve both sensitivity and specificity [7]. In addition,
another autoantibody designated by Shi et al. [8] as anti-
CarP antibodies has been described as a disease marker in
RA patients and targets carbamylated proteins rather than
citrullinated proteins. Carbamylation involves a post-
translational modification of lysine to homocitrulline
under the influence of cyanate [9]. Increased carbamyla-
tion is related to chronic inflammatory conditions [10].
Anti-CarP antibodies are present in both anti-CCP-positive
and anti-CCP-negative patients and may predict the
development of RA, independent of anti-CCP antibodies
[11–13].
Inflammatory bowel disease (IBD) is associated with
various extra-intestinal manifestations, including arthro-
pathies, with a prevalence of ∼30% [14]. IBD-associated
arthropathies can be subdivided into inflammatory
(spondyloarthritis; SpA) on the basis of the rheumatolo-
gical ASAS criteria for axial and peripheral SpA and
noninflammatory (arthralgia) joint complaints [15].
Although previous studies report a genetic link, with
shared susceptibility genes between RA patients and
arthropathies in IBD [16], less is known about the presence
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of serological RA biomarkers in IBD patients with
arthropathies. Therefore, in the present study, we exam-
ined the presence of RA biomarkers in IBD patients with
arthropathies and compared biomarker positivity in these




The inclusion procedure of IBD patients was as described
previously [15]. Briefly, serum samples were collected from
254 IBD patients included in the JOINT study, a single-
center prospective longitudinal study focused on IBD
patients with and without arthropathies, carried out at the
Department of Gastroenterology and Hepatology of the
Leiden University Medical Center, The Netherlands.
Patients visiting the IBD outpatient clinic from July 2009
to February 2010 were asked to complete a questionnaire
to assess the presence of joint complaints during the pre-
vious year. Patients with self-reported joint and/or back
pain (n=155) were invited to attend the JOINT outpatient
clinic. This clinic was established by the Department of
Gastroenterology and Hepatology and the Department of
Rheumatology to expand the knowledge of IBD joint
complaints. All IBD patients without self-reported joint
complaints served as controls (n=99). At the JOINT
outpatient clinic, medical history and data on extra-
intestinal manifestations were collected. In addition to
routine physical examination, a rheumatologic examina-
tion was performed in all IBD patients, including a detailed
assessment of the number of tender and swollen joints.
Laboratory assessments included the erythrocyte sedi-
mentation rate and the C-reactive protein. HLA-B27 was
only typed in patients with chronic back pain and/or per-
ipheral joint complaints. Of the 155 patients with self-
reported arthropathies, 63 (40.6%) were classified
according to the different SpA classification criteria as
reported previously [15]. Of these patients, 19 (12.3%)
patients fulfilled the ASAS criteria for axial and peripheral
SpA, the classification criteria used most often in clinical
trials and the most practical system with which to classify
SpA [15,17]. Eventually, in total, 15 (9.6%) patients were
diagnosed with arthritis by a rheumatologist (F.v.G.).
For the current protocol, the presence of the different
serological biomarkers in 147 RA patients from the early
arthritis clinic was used as a comparison. This inception
cohort includes patients with arthritis with a duration of
the complaints of less than 2 years. After 1 year of follow-
up, a final diagnosis was established and for this mea-
surement, only baseline samples of patients who were
diagnosed with RA and fulfilled the 1987 criteria were
used [18]. The study was approved by the institutional
medical ethical committee of the Leiden University
Medical Center and patients signed a written informed
consent before study enrollment, including the biobanking
protocol.
Measurement of serologic biomarkers
Serum levels of IgM-RF, IgA-RF, anti-CCP2, anti-CCP3.1,
and anti-CarP IgG and IgA were determined using an
enzyme-linked immunosorbent assay; the cutoff value used
for anti-CCP2 was 25.0 AU/ml. For anti-CarP antibodies,
the cutoff was established as the mean + 2× SD of 200
healthy controls, as before [8]. Cutoff levels of IgM-RF,
IgA-RF, and anti-CCP3.1 were 6.0, 6.0, and 20.0 AU/ml
according to the manufacturer’s (Inova Diagnostics Inc.,
San Diego, California, USA) recommendation. Positivity of
IgM-RF, IgA-RF, anti-CCP2, anti-CCP3.1, and anti-CarP
in IBD patients with arthropathies was compared with
those without arthropathies and RA patients.
Statistical analysis
Statistical analysis was carried out using SPSS, version 23.0
software (IBM Corp., Armonk, New York, USA). χ2 and
Student’s t-tests for independent samples were used to
compare the biomarker positivity in IBD patients with
arthropathies with IBD patients without arthropathies and
RA patients. Logistic regression analysis, with the different
biomarkers as a dependent variable, was carried out to
assess variables associated with a positive biomarker.
Univariate analyses were carried out for several variables
including age, sex, type of IBD, IBD disease activity (Harvey
Bradshaw Index or Simple Clinical Colitis Activity
Index>4), smoking, arthritis (diagnosed by the rheuma-
tologist), or SpA, classified according to the different SpA
classification criteria [15]. Variables with a statistical level
of P-value less than 0.1 in the univariate analysis were
included in the multivariate analysis. A P-value less than or
equal to 0.05 was considered statistically significant.
Results
Characteristics of the 254 patients with and without
arthropathies are presented in Table 1. IBD patients with
arthropathies were significantly more often diagnosed with
Crohn’s disease (CD), more frequently females and smo-
kers. No differences in biomarker positivity were found
between IBD patients with and without arthropathies.
Univariate analysis in all IBD patients showed that female
sex [odds ratio (OR)= 0.5, 95% confidence interval
(CI)=0.25–0.99, P=0.05] and smoking (OR=2.4, 95%









Crohn’s disease 121 (78.1) 66 (66.7) 0.04
Ulcerative colitis 34 (21.9) 33 (33.3)
Male 46 (29.7) 50 (50.5) 0.001
Age at inclusion
(mean ±SD) (years)
43.4 ± 13.6 42.7 ±13.6 0.70
Age of IBD onset
(mean ±SD) (years)
27.5 ± 11.3 25.9 ±10.1 0.26
IBD disease duration
(mean ±SD) (years)
15.4 ± 11.8 16.3 ±11.1 0.54
Smoker 47 (30.0) 13 (13.1) 0.001
Positive IgM-RF 36 (23.2) 15 (15.2) 0.12
Positive IgA-RF 6 (3.9) 3 (3.0) 0.73
Positive anti-CCP2 0 (0) 0 (0) –
Positive anti-CCP3.1 6 (3.8) 5 (5.0) 0.71
Positive anti-CarP IgG 4 (2.6) 2 (2.0) 0.77
Positive anti-CarP IgA 10 (6.5) 8 (8.1) 0.62
CarP, carbamylated protein; CCP, cyclic citrullinated peptide; IBD, inflammatory
bowel disease; Ig, immunoglobulin; RF, rheumatoid factor.
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CI= 1.21–4.55, P= 0.01) were associated with a risk of
having a positive IgM-RF antibody test. In the multivariate
analysis, smoking (OR=0.44, 95% CI= 0.22–0.85,
P= 0.02) remained independently associated with a posi-
tive IgM-RF test. In the univariate analysis for IgA-RF,
smoking turned out to be significantly associated
(OR=4.3, 95% CI=1.12–6.60, P= 0.03) with a positivity
for IgA-RF.
When a subdivision was performed within the group of
IBD patients with arthropathies on the basis of CD and
ulcerative colitis (UC), significantly more UC patients were
positive in the anti-CarP IgG antibody test [CD: 1 (0.8%)
vs. UC: 3 (8.8%), P= 0.009]. In addition, positivity of
IgM-RF, IgA-RF, anti-CCP2, anti-CCP3.1, anti-CarP IgG,
and anti-CarP IgA in IBD patients with arthropathies was
compared with RA patients (Fig. 1). Approximately 40%
of the IBD patients with arthropathies were classified with
SpA and were significantly less frequently positive for IgM-
RF, anti-CCP2, anti-CCP3.1, anti-CarP IgA, and anti-
CarP IgG antibodies biomarkers (P<0.001) compared
with the RA patients (Fig. 1).
When the 15 IBD patients with arthritis were compared
with the 239 IBD patients without arthritis, none of the
biomarkers were significantly more prevalent in the group
of patients with both IBD and arthritis.
Discussion
In the present study, RA biomarkers were assessed in IBD
patients with and without arthropathies and the frequency
of biomarker positivity was compared with RA patients.
The RA markers were infrequently present in the IBD
patients, with no significant differences in positivity
between IBD patients with and without arthropathies. A
striking difference in autoantibody positivity was observed
when comparing IBD patients with arthropathies with RA
patients. In addition, as found in RA, smoking seems to be
related to IgM-RF and IgA-RF positivity in IBD [19,20].
Although anti-CCP is highly specific for RA, previous
studies have shown the occurrence of positive anti-CCP
antibodies in other arthropathies such as psoriatic arthritis
and IBD patients [21–24]. Haga et al. [22] concluded that
the prevalence of anti-CCP IgA antibodies in IBD patients
is low (1.2%), but significantly associated with arthritis
and IgM RF positivity. However, in studies of Papamichael
and colleagues [23,24], no significant association was
found between the prevalence of anti-CCP positivity and
IBD-related arthropathies. This is in agreement with the
present study; in none of the IBD patients was anti-CCP2
detected and in 11 (6/155=3.8% with arthropathies
and 5/99= 5% without) IBD patients, anti-CCP3.1 was
present.
Although the presence of anti-CCP2 and anti-CCP3.1 in
IBD patients has been examined previously [22–24], posi-
tivity for other possible arthropathy-related biomarkers has
not been reported in IBD patients before. In the present
study, besides the presence of anti-CCP2 and anti-CCP3.1,
IgM-RF, IgA-RF, and anti-CarP antibodies were assessed in
the sera of IBD patients with and without arthropathies. In
contrast to the increased sensitivity in RA patients achieved
by combinations of these biomarkers, they did not add
clinical value. Recently, Shi et al. [8] reported that anti-CarP
are the most sensitive antibodies that are present before RA
becomes clinically apparent. In our study, anti-CarP was
detected in only four (2.6%) IBD patients with arthro-
pathies compared with 66 (42.6%) RA patients.
In the present study, smoking seems to be related to a
positive IgM-RF and IgA-RF in IBD patients with arthro-
pathies and supports the findings by Mikuls et al. [25] in
which current smokers were approximately twice as likely
as never smokers to have increased IgA-RF concentrations.
This association was most pronounced in the patients with
more than 20 pack-years of exposure.
An important strength of this study is the well-defined
study cohort, with all IBD patients classified thoroughly
with or without SpA. Second, all different biomarkers
known in RA patients were evaluated in this study design in
IBD patients and compared with RA patients. A limitation
of this study is the limited number of 15 patients with
proven arthritis after rheumatologic examination, although
a total of 63 patients fulfilled one of the clinical SpA criteria.
No difference in biomarker positivity was found between
these 15 IBD patients with and 239 IBD patients without
arthritis. Probably, the total of all 15 IBD patients diag-
nosed with arthritis was too small to make this difference.
Taken together, our data show that the presence of
arthropathies in IBD is not accompanied by the presence of
different RA serological biomarkers. The differences
between positivity in IBD patients with arthropathies and
RA patients suggest that the immunopathogenesis of
arthropathies in IBD may differ from mechanisms in RA
patients. More studies are required to investigate these
differences. Furthermore, this study implies that there is no
apparent clinical value in detecting these RA biomarkers in
the serum of IBD patients with arthropathies.
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Fig. 1. Differences in biomarker positivity between IBD and RA patients.
Comparisons of the positivity of IgA-RF, anti-CCP2, IgM-RF, anti-CCP3.1,
anti-CarP IgG, and anti-CarP IgA in IBD patients with arthropathies (IBD+ ),
IBD patients without arthropathies (IBD− ) and RA patients. IgA-RF is not
determined (n.d.) in the RA patients. *P<0.001. CarP, carbamylated protein;
CCP, cyclic citrullinated peptide; IBD, inflammatory bowel disease; Ig,
immunoglobulin; RA, rheumatoid arthritis; RF, rheumatoid factor.
Biomarkers in inflammatory bowel disease Van Erp et al. www.eurojgh.com 347
Copyright r 2017 Wolters Kluwer Health, Inc. All rights reserved.
References
1 Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK.
Severe functional declines, work disability, and increased mortality in
seventy-five rheumatoid arthritis patients studied over nine years.
Arthritis Rheum 1984; 27:864–872.
2 Landewé RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA,
Markusse HM, et al. COBRA combination therapy in patients with early
rheumatoid arthritis: long-term structural benefits of a brief intervention.
Arthritis Rheum 2002; 46:347–356.
3 Landewé RBM. The benefits of early treatment in rheumatoid arthritis:
confounding by indication, and the issue of timing. Arthritis Rheum
2003; 48:1–5.
4 Ingegnoli F, Castelli R, Gualtierotti R. Rheumatoid factors: clinical
applications. Dis Markers 2013; 35:727–734.
5 Kudo-Tanaka E, Ohshima S, Ishii M, Mima T, Matsushita M, Azuma N,
et al. Autoantibodies to cyclic citrullinated peptide 2 (CCP2) are superior
to other potential diagnostic biomarkers for predicting rheumatoid
arthritis in early undifferentiated arthritis. Clin Rheumatol 2007;
26:1627–1633.
6 Bos WH, Wolbink GJ, Boers M, Tijhuis GJ, de Vries N, van der Horst-
Bruinsma IE, et al. Arthritis development in patients with arthralgia is
strongly associated with anti-citrullinated protein antibody status:
a prospective cohort study. Ann Rheum Dis 2010; 69:490–494.
7 Dos Anjos LM, Pereira IA, d’Orsi E, Seaman AP, Burlingame RW,
Morato EF. A comparative study of IgG second- and third generation
anti-cyclic citrullinated peptide (CCP) ELISAs and their combination with
IgA third-generation CCP ELISA for the diagnosis of rheumatoid arthritis.
Clin Rheumatol 2009; 28:153–158.
8 Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GMC,
van Veelen PA, et al. Autoantibodies recognizing carbamylated
proteins are present in sera of patients with rheumatoid arthritis
and predict joint damage. Proc Natl Acad Sci USA 2011; 108:
17372–17377.
9 Shi J, van Veelen PA, Mahler M, Janssen GM, Drijfhout JW,
Huizinga TW, et al. Carbamylation and antibodies against carbamylated
proteins in autoimmunity and other pathologies. Autoimmun Rev 2014;
13:225–230.
10 Verheul MK, van Erp SJ, van der Woude D, Levarht EW, Mallat MJ,
Verspaget HW, et al. Anti-carbamylated protein antibodies: a specific
hallmark for rheumatoid arthritis. Comparison to conditions known for
enhanced carbamylation; renal failure, smoking and chronic inflamma-
tion. Ann Rheum Dis 2016; 75:1575–1576.
11 Shi J, van de Stadt LA, Levarht EWN, Huizinga TWJ, Toes REM,
Trouw LA, et al. Anti-carbamylated protein antibodies are present in
arthralgia patients and predict the development of rheumatoid arthritis.
Arthritis Rheum 2013; 65:911–915.
12 Gan RW, Trouw LA, Shi J, Toes RE, Huizinga TW, Demoruelle MK, et al.
Anti-carbamylated protein antibodies are present prior to rheumatoid
arthritis and are associated with its future diagnosis. J Rheumatol 2015;
42:572–579.
13 Ryu Jung H, Takeuchi F, Kuwata S, Kim YJ, Lee EY, Lee EB, et al. The
diagnostic utilities of anti-agalactosyl IgG antibodies, anti-cyclic citrulli-
nated peptide antibodies, and rheumatoid factors in rheumatoid
arthritis. Rheumatol Int 2011; 31:315–319.
14 De Vlam K, Mielants H, Cuvelier C, de Keyser F, Veys EM, de Vos M.
Spondyloarthropathy is underestimated in inflammatory bowel disease:
prevalence and HLA association. J Rheumatol 2000; 27:2860–2865.
15 Van Erp SJ, Brakenhoff LK, van Gaalen FA, van den Berg R, Fidder HH,
Verspaget HW, et al. Classifying back pain and peripheral joint com-
plaints in inflammatory bowel disease patients: a prospective long-
itudinal follow-up study. J Crohns Colitis 2016; 10:166–175.
16 Brophy S, Pavy S, Lewis P, Taylor G, Bradbury L, Robertson D, et al.
Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic,
phenotypic, and environmental factors. J Rheumatol 2001; 28:2667–2673.
17 Raychaudhuri S, Deodhar A. The classification and diagnostic criteria of
ankylosing spondylitis. J Autoimmun 2014; 48-49:128–133.
18 Van Aken J, van Bilsen JH, Allaart CF, Huizinga TW, Breedveld FC. The
Leiden Early Arthritis Clinic. Clin Exp Rheumatol 2003; 21 (Suppl 31):
S100–S105.
19 Linn-Rasker SP, van der Helm-van Mil AHM, van Gaalen FA,
Kloppenburg M, de Vries RRP, le Cessie S, et al. Smoking is a risk factor
for anti-CCP antibodies only in rheumatoid arthritis patients who carry
HLA-DRB1 shared epitope alleles. Ann Rheum Dis 2006; 65:366–371.
20 Krol A, Garred P, Heegaard NH, Christensen AF, Hetland ML,
Stengaard-Pedersen K, et al. Interactions between smoking, increased
serum levels of anti-CCP antibodies, rheumatoid factors, and erosive
joint disease in patients with early, untreated arthritis. Scand J
Rheumatol 2015; 44:8–12.
21 Bogliolo L, Alpini C, Caporali R, Scirè CA, Moratti R, Montecucco C.
Antibodies to cyclic citrullinated peptides in psoriatic arthritis.
J Rheumatol 2005; 32:511–515.
22 Haga HJ, Palm Ø, Peen E. Prevalence of IgA class antibodies to cyclic
citrullinated peptide in patients with inflammatory bowel disease (IBD).
Clin Rheumatol 2011; 30:955–957.
23 Papamichael K, Tsirogianni A, Papasteriades C, Mantzaris GJ. Low
prevalence of antibodies to cyclic citrullinated peptide in patients with
inflammatory bowel disease regardless of the presence of arthritis. Eur J
Gastroenterol Hepatol 2010; 22:705–709.
24 Koutroubakis IE, Karmiris K, Bourikas L, Kouroumalis EA,
Drygiannakis I, Drygiannakis D. Antibodies against cyclic citrullinated
peptide (CCP) in inflammatory bowel disease patients with or without
arthritic manifestations. Inflamm Bowel Dis 2007; 13:504–505.
25 Mikuls TR, Hughes LB, Westfall AO, Holers VM, Parrish L, van der
Heijde D, et al. Cigarette smoking, disease severity and autoantibody
expression in African Americans with recent-onset rheumatoid arthritis.
Ann Rheum Dis 2008; 67:1529–1534.
348 European Journal of Gastroenterology & Hepatology March 2017 •Volume 29 •Number 3
Copyright r 2017 Wolters Kluwer Health, Inc. All rights reserved.
